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R. helvetica (5), R. slovaca (6), and R.
felis (7). The serologic findings indi-
cated antibodies at a higher level to R.
aeschlimannii than to other tested spe-
cies. R. aeschlimannii is phylogeneti-
cally distant from R. conorii but is
closely related to R. rhipicephali and
R. montanensis, which have never
been described as human pathogens.
This patient appeared to have a typical
case of R. conorii infection, with sea-
sonal and geographic characteristics
favoring this diagnosis (3). This case
was clinically and epidemiologically
mistaken for R. conorii infection, sug-
gesting that R. aeschlimanii may be
another cause of Mediterranean spot-
ted fever in Morocco. 
The systematic identification of
rickettsial species in human infections
continues to increase the number of
recognized human pathogens (3). This
finding has demonstrated once again
that more than one species or serotype
of tick-transmitted rickettsia may be
prevalent in the same area, as
observed, for example, with R. slo-
vaca, “R. mongolotimonae,”  and  R.
conorii in southern France (3); R. afri-
cae and R. conorii in sub-Saharan
Africa (8); and R. conorii and Israeli
spotted fever rickettsia in Sicily and
Portugal (9). Rickettsia species first
identified in ticks should be consid-
ered as potential human pathogens, as
all recently described tick-transmitted
rickettsiae pathogenic for humans
were initially found in ticks and were
considered nonpathogenic for several
years (3).
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Cost-Effective 
Screening for 
Trichomoniasis
To the Editor:  I read with interest
a recent article in your journal,  “Tri-
chomonas vaginalis, HIV, and African
Americans” (1), and I commend the
authors’ suggestion to implement
screening and reporting of trichomoni-
asis for high-risk populations. 
In the article, a cost-effective
screening approach is mentioned,
which includes culturing only for
those women whose wet-mount tests
are negative. In 1999, my colleagues
and I reported on the validity of this
method for diagnosing trichomoniasis
in women (2). During our study, an
additional vaginal swab was collected
during the pelvic examination and
placed into a glass tube. If the wet
mount was negative, this swab was
later added to a culture pouch for T.
vaginalis. We found no statistically
significant difference in the sensitivity
of this method compared with that of
adding swabs immediately to pouches
at bedside. This method of delaying
the second test until the results of the
first test are known should be consid-
ered in screening women for tri-
chomoniasis, especially in high-
prevalence populations.
Jane R. Schwebke
University of Alabama at Birmingham, Bir-
mingham, Alabama, USA
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Reply to Dr. Schwebke
To the Editor:  We welcome Dr.
Schwebke’s thoughtful comments
about decreasing the cost of screening
for  Trichomonas vaginalis. Dr.
Schwebke and her colleagues have
demonstrated that storing a vaginal
swab for 15–20 minutes in a glass tube
at room temperature does not affect
the viability of T. vaginalis or reduce
the sensitivity of subsequent culture.
This finding shows that vaginal swabs
may be stored briefly while a wet-
mount preparation is made and exam-
ined. If the wet mount is negative for
T. vaginalis, the stored swab can then
be processed for culture. If the wet
mount is positive for T. vaginalis, no
further culture of the specimen is
needed, thereby reducing unnecessary
costs.  Given that the prevalence of
this infection often exceeds 20% in
high-risk populations, this approach
can reduce costs substantially without
compromising the accuracy of the
tests. Any method that reduces the
cost of diagnosis will advance further